25 results on '"Latusek T"'
Search Results
2. PO-1701 STereotactic Arrhythmia Radioablation in Europe–Treatment Unit QA Audit of the STOPSTORM Consortium
- Author
-
Dolla, Ł., primary, Grządziel, A., additional, Bekman, A., additional, Blamek, S., additional, Latusek, T., additional, Miszczyk, M., additional, Verhoeff, J.J., additional, Grehn, M., additional, and Blanck, O., additional
- Published
- 2023
- Full Text
- View/download PDF
3. PO-1057 Interim analysis of a prospective ventricular tachycardia radioablation safety trial (NCT04642963)
- Author
-
Miszczyk, M., primary, Sajdok, M., additional, Jadczyk, T., additional, Kurzelowski, R., additional, Latusek, T., additional, Gołba, K., additional, Bednarek, J., additional, Dolla, Ł., additional, Grządziel, A., additional, Zub, K., additional, Tomasik, B., additional, Cybulska, M., additional, Gardas, R., additional, Drzewiecka, A., additional, Wojakowski, W., additional, Wita, K., additional, and Blamek, S., additional
- Published
- 2022
- Full Text
- View/download PDF
4. PO-1445 Radiotherapy - a safe and successful treatment for plantar fasciitis.
- Author
-
Latusek, T., primary, Gabrys, D., additional, Wozniak, G., additional, Graupner, D., additional, Krzywon, A., additional, and Cortez, A.J., additional
- Published
- 2022
- Full Text
- View/download PDF
5. PD-0750 Outcome after stereotactic body radiotherapy (SBRT) for oligometastatic breast cancer patients
- Author
-
Gräupner, D., primary, Latusek, T., additional, Kulik, R., additional, and Gabryś, D., additional
- Published
- 2022
- Full Text
- View/download PDF
6. PO-1519 Efficacy and safety of radiotherapy for Epicondylitis Humeri (EPH)
- Author
-
Latusek, T., primary, Gabryś, D., additional, Woźniak, G., additional, Krzywon, A., additional, Cortez, A.J., additional, and Miszczyk, L., additional
- Published
- 2021
- Full Text
- View/download PDF
7. SP-0355 SBRT as a strategy to delay systemic treatment in metastatic breast cancer
- Author
-
Gabrys, D., primary, Kulik, R., additional, Graupner, D., additional, Latusek, T., additional, Debosz-Suwinska, I., additional, Roch-Zniszczol, A., additional, and Namysl-Kaletka, A., additional
- Published
- 2021
- Full Text
- View/download PDF
8. Serum Micrornas As Biomarkers Of HPV-Associated Oropharyngeal Cancer
- Author
-
Tomasik, B., primary, Papis-Ubych, A., additional, Kedzierawski, P., additional, Bibik, R., additional, Latusek, T., additional, Stando, R., additional, Kowalik, A., additional, Sadowski, J., additional, Graczyk, L., additional, Mazurek, A., additional, Śnietura, M., additional, Rutkowski, T., additional, Fijuth, J., additional, Widłak, P., additional, and Fendler, W., additional
- Published
- 2020
- Full Text
- View/download PDF
9. OC-0323: Serum microRNAs as xerostomia biomarkers in oropharyngeal cancer patients undergoing radiotherapy
- Author
-
Tomasik, B., primary, Papis-Ubych, A., additional, Fijuth, J., additional, Kędzierawski, P., additional, Sadowski, J., additional, Stando, R., additional, Bibik, R., additional, Graczyk, Ł., additional, Latusek, T., additional, Rutkowski, T., additional, Widłak, P., additional, and Fendler, W., additional
- Published
- 2020
- Full Text
- View/download PDF
10. PO-1305: Effectiveness and safety evaluation of radiotherapy for Painful Heel Spur Syndrome.
- Author
-
Latusek, T., primary and Miszczyk, L., additional
- Published
- 2020
- Full Text
- View/download PDF
11. EP-1265 Total Skin Irradiation -15 years of Gliwice experiences
- Author
-
Wozniak, G., primary, Latusek, T., additional, Kaniszewska-Dorsz, Z., additional, Mista, W., additional, Jochymek, B., additional, Lukasz, K., additional, Jerzy, W., additional, and Blamek, S., additional
- Published
- 2019
- Full Text
- View/download PDF
12. EP-1680 The effectivenes and safety evaluation of radiotherapy for painful humeroscapular periarthritis(PHS)
- Author
-
Latusek, T., primary, Wozniak, G., additional, and Miszczyk, L., additional
- Published
- 2019
- Full Text
- View/download PDF
13. EP-1709: An effectiveness evaluation of the palmar fascia irradiation of patients with Dupuytren’s disease
- Author
-
Latusek, T., primary, Miszczyk, L., additional, Gierlach, G., additional, and Zając, P., additional
- Published
- 2018
- Full Text
- View/download PDF
14. EP-1276: Clinic and radiobiology of hypofractionated radiotherapy for metastatic liver tumors. Pilot results
- Author
-
Latusek, T., primary, Miszczyk, L., additional, and Rembak-Szynkiewicz, J., additional
- Published
- 2017
- Full Text
- View/download PDF
15. Stereotactic management of arrhythmia - radiosurgery in treatment of ventricular tachycardia (SMART-VT). Results of a prospective safety trial.
- Author
-
Miszczyk M, Sajdok M, Bednarek J, Latusek T, Wojakowski W, Tomasik B, Wita K, Jadczyk T, Kurzelowski R, Drzewiecka A, Cybulska M, Gardas R, Jarosiński G, Dolla Ł, Grządziel A, Zub K, Bekman A, Kaminiów K, Kozub A, Gołba KS, and Blamek S
- Abstract
Background and Purpose: Despite its increasing popularity, there are limited prospective data on stereotactic arrhythmia radioablation (STAR). In this trial, we assessed the safety and efficacy of STAR in patients with ventricular tachycardia (VT), focusing on early treatment-related grade ≥ 3 adverse events (AE)., Materials and Methods: This prospective trial was designed for adults with VT recurrence following catheter ablation (CA) despite adequate pharmacotherapy, or contraindications to CA. A single dose of 25 Gy was delivered to the arrhythmia substrate defined on electro-anatomic mapping and cardiac-gated CT. The primary endpoint was safety, defined as two or fewer treatment-related grade ≥ 3 AEs during the first three months in 11 patients. Additional endpoints included treatment efficacy, clinical and biological markers of cardiac injury, and quality of life., Results: Eleven patients with a median age of 67 years, structural heart disease, and a clinically significant recurrence of VT despite adequate pharmacotherapy and 1-4 previous CAs were enrolled between 2020/09 and 2022/10. Following the treatment, one patient developed a possibly treatment-related grade ≥ 3 AE, a grade 4 heart failure exacerbation at 87 days, which resolved after conservative treatment. There was a total 84.3% reduction in VT burden in 10 evaluable patients; however, VT recurrence was eventually observed in eight, and three patients required additional CAs. Three deaths due to unrelated causes were recorded., Conclusions: STAR appears to be safe and efficient. It is a promising treatment for selected patients; however, long-term outcomes remain to be evaluated, and controlled trials comparing STAR with standards of care are missing., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer.
- Author
-
Kubeczko M, Gabryś D, Gawkowska M, Polakiewicz-Gilowska A, Cortez AJ, Krzywon A, Woźniak G, Latusek T, Leśniak A, Świderska K, Mianowska-Malec M, Łanoszka B, Chomik K, Gajek M, Michalik A, Nowicka E, Tarnawski R, Rutkowski T, and Jarząb M
- Abstract
The addition of CDK4/6 inhibitors to endocrine therapy in advanced hormone receptor-positive HER2-negative breast cancer has led to practice-changing improvements in overall survival. However, data concerning the safety of CDK4/6i combination with radiotherapy (RT) are conflicting. A retrospective evaluation of 288 advanced breast cancer patients (pts) treated with CDK4/6i was performed, and 100 pts also received RT. Forty-six pts received 63 RT courses concurrently and fifty-four sequentially before CDK4/6i initiation (76 RT courses). Neutropenia was common (79%) and more frequent during and after concurrent RT than sequential RT (86% vs. 76%); however, CDK4/6i dose reduction rates were similar. In patients treated with CDK4/6i alone, the dose reduction rate was 42% (79 pts) versus 38% with combined therapy, and 5% discontinued treatment due to toxicity in the combined group. The risk of CDK4/6i dose reduction was correlated with neutropenia grade, RT performed within the first two CDK4/6i cycles, and more than one concurrent RT; a tendency was observed in concurrent bone irradiation. However, on multivariate regression analysis, only ECOG 1 performance status and severe neutropenia at the beginning of the second cycle were found to be associated with a higher risk of CDK4/6i dose reduction. This largest single-center experience published to date confirmed the acceptable safety profile of the CDK4/6i and RT combination without a significantly increased toxicity compared with CDK4/6i alone. However, one might delay RT for the first two CDK4/6i cycles, when myelotoxic AE are most common.
- Published
- 2023
- Full Text
- View/download PDF
17. Histopathological Examination of an Explanted Heart in a Long-Term Responder to Cardiac Stereotactic Body Radiotherapy (STereotactic Arrhythmia Radioablation).
- Author
-
Miszczyk M, Sajdok M, Nożyński J, Cybulska M, Bednarek J, Jadczyk T, Latusek T, Kurzelowski R, Dolla Ł, Wojakowski W, Dyla A, Zembala M, Drzewiecka A, Kaminiów K, Kozub A, Chmielik E, Grza Dziel A, Bekman A, Gołba KS, and Blamek S
- Abstract
Cardiac stereotactic body radiotherapy is an emerging treatment method for recurrent ventricular tachycardia refractory to invasive treatment methods. The single-fraction delivery of 25 Gy was assumed to produce fibrosis, similar to a post-radiofrequency ablation scar. However, the dynamics of clinical response and recent preclinical findings suggest a possible different mechanism. The data on histopathological presentation of post-radiotherapy hearts is scarce, and the authors provide significantly different conclusions. In this article, we present unique data on histopathological examination of a heart explanted from a patient who had a persistent anti-arrhythmic response that lasted almost a year, until a heart failure exacerbation caused a necessity of a heart transplant. Despite a complete treatment response, there was no homogenous transmural fibrosis in the irradiated region, and the overall presentation of the heart was similar to other transplanted hearts of patients with advanced heart failure. In conclusion, our findings support the theorem of functional changes as a source of the anti-arrhythmic mechanism of radiotherapy and show that durable treatment response can be achieved in absence of transmural fibrosis of the irradiated myocardium., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Miszczyk, Sajdok, Nożyński, Cybulska, Bednarek, Jadczyk, Latusek, Kurzelowski, Dolla, Wojakowski, Dyla, Zembala, Drzewiecka, Kaminiów, Kozub, Chmielik, Grza̧dziel, Bekman, Gołba and Blamek.)
- Published
- 2022
- Full Text
- View/download PDF
18. Radiosurgery in Treatment of Ventricular Tachycardia - Initial Experience Within the Polish SMART-VT Trial.
- Author
-
Kurzelowski R, Latusek T, Miszczyk M, Jadczyk T, Bednarek J, Sajdok M, Gołba KS, Wojakowski W, Wita K, Gardas R, Dolla Ł, Bekman A, Grza Dziel A, and Blamek S
- Abstract
Background: Stereotactic Arrhythmia Radioablation (STAR) is an emerging treatment modality for patients with sustained ventricular tachycardia (VT) and refractory to treatment with drugs and radiofrequency catheter ablation (RFA). It is believed that up to 12-17% of patients experience recurrence of VT within 1 year of follow-up; thus, novel therapeutic options are needed. The aim of this article is to present initial experience within a novel treatment modality for VT., Case Summary: Two patients with a medical history of coronary artery disease and heart failure with reduced left ventricle (LV) ejection fraction, after implantation of cardioverter-defibrillator (ICD) and previous unsuccessful RFAs owing to sustained VT were admitted to the cardiology department due to recurrence of sustained VT episodes. With electroanatomical mapping (EAM), the VT substrate in LV has been confirmed and specified. In order to determine the target volume for radioablation, contrast-enhanced computed tomography was performed and the arrhythmia substrate was contoured using EAM data. Using the Volumetric Modulated Arc Therapy technique and three 6 MeV flattening filter-free photon beam fields, a single dose of 25 Gy was delivered to the target volume structure located in the apex and anterior apical segments of LV in the first patient and in the apex, anterolateral and inferior apical segments of the second patient. In both cases, volumes of the target structures were comparable. Interrogation of the implanted ICD at follow-up visits throughout 6 months after the treatment revealed no VT episodes in the first patient and sudden periprocedural increase in VT burden with a subsequent gradual decrease of ventricular arrhythmia to only two non-sustained episodes at the end of the follow-up period in case of the second patient. A significant reduction in premature ventricular contractions burden was observed compared to the pre-treatment period. No noticeable deterioration in LV function was noted, nor any adverse effects of radiosurgery associated with the implanted device., Conclusion: The early response to STAR can be unpredictable and probably does not reflect the final outcome of irradiation. Close monitoring of patients, especially in the early period after irradiation is crucial to properly handle potentially harmful early reactions to STAR., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Kurzelowski, Latusek, Miszczyk, Jadczyk, Bednarek, Sajdok, Gołba, Wojakowski, Wita, Gardas, Dolla, Bekman, Grza̧dziel and Blamek.)
- Published
- 2022
- Full Text
- View/download PDF
19. Stereotactic arrhythmia radioablation in recurrent ventricular tachyarrhythmias.
- Author
-
Cybulska M, Sajdok M, Bednarek J, Miszczyk M, Jadczyk T, Kurzelowski R, Gardas R, Drzewiecka A, Jarosiński G, Zub K, Latusek T, Wojakowski W, Blamek S, and Gołba K
- Subjects
- Arrhythmias, Cardiac, Humans, Imaging, Three-Dimensional, Ventricular Fibrillation, Tachycardia, Ventricular surgery
- Published
- 2022
- Full Text
- View/download PDF
20. Serum MicroRNAs as Xerostomia Biomarkers in Patients With Oropharyngeal Cancer Undergoing Radiation Therapy.
- Author
-
Tomasik B, Papis-Ubych A, Stawiski K, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, and Fendler W
- Subjects
- Biomarkers, Biomarkers, Tumor, Humans, MicroRNAs, Prospective Studies, Radiation Injuries genetics, Oropharyngeal Neoplasms genetics, Oropharyngeal Neoplasms radiotherapy, Xerostomia etiology
- Abstract
Purpose: Severe xerostomia is noted in the majority of patients irradiated for oropharyngeal cancer. Extracellular microRNAs (miRNAs) may serve as effective tools allowing prediction of radiation-related toxicity. The aim of this study was to create an efficient prognostic miRNA-based test for severe, patient-rated xerostomia 3 months after primary treatment., Methods and Materials: This prospective study enrolled patients with oropharyngeal cancer treated between 2016 and 2018 in 3 centers in Poland. The primary endpoint was severe (grade ≥3) xerostomia as assessed by the European Organisation for Research and Treatment of Cancer H&N-35 questionnaires. Initially, a group of 10 patients with severe xerostomia was randomly selected and matched with a comparative group of 10 patients without severe xerostomia. Samples were collected before radiation therapy, after receiving 20 Gy, and within 24 hours after treatment completion. Quantitative real-time polymerase chain reaction arrays (QIAGEN, Hilden, Germany) were used to quantify expression levels of 752 miRNAs in the serum at all timepoints. The resulting logistic-regression based model was validated in additional 60 patients: 30 with grade >3 xerostomia and 30 without., Results: Of 152 eligible patients, we successfully recruited 111 patients. Severe xerostomia 3 months after treatment was reported by 63 patients (56.8%). Mean dose delivered to parotid glands was higher in both the exploratory and validation cohort. The model based on miR-185-5p and miR-425-5p expression levels measured before the start of radiation therapy had an area under the curve of 0.96 (95% confidence interval, 0.88-1.00). The model based on the same miRNAs remained robust when parameters were measured after 20 Gy (area under the curve 0.90; 95% confidence interval, 0.75-1.00). These results were confirmed in the validation group. In the validation group, preradiation therapy model application yielded 73.3% sensitivity and 80.0% specificity. In the samples taken after 20 Gy, the same 2 miRNAs yielded 67.7% sensitivity and 72.4% specificity. The model including pretreatment miR-185-5p and miR-425-5p levels together with mean parotid dose yielded 90.0% sensitivity and 80.0% specificity. In the validation cohort, this model yielded 80.6% sensitivity and 55.2% specificity. The model based on miRNA levels measured after 20 Gy and mean parotid dose had 80.0% sensitivity and 100% specificity in the exploratory group. In the validation cohort its performance fell to 71.0% sensitivity and 58.6% specificity., Conclusions: Serum expression levels of miR-425-5p and miR-185-5p measured before the start of radiation therapy or during therapy (after 20 Gy) had significant prognostic value for the occurrence of severe xerostomia 3 months after treatment completion. The variability explained by miRNAs appears to be, at least partially, independent from that related to the dosimetric data., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Prediction of Radiation-Induced Hypothyroidism Using Radiomic Data Analysis Does Not Show Superiority over Standard Normal Tissue Complication Models.
- Author
-
Smyczynska U, Grabia S, Nowicka Z, Papis-Ubych A, Bibik R, Latusek T, Rutkowski T, Fijuth J, Fendler W, and Tomasik B
- Abstract
State-of-art normal tissue complication probability (NTCP) models do not take into account more complex individual anatomical variations, which can be objectively quantitated and compared in radiomic analysis. The goal of this project was development of radiomic NTCP model for radiation-induced hypothyroidism (RIHT) using imaging biomarkers (radiomics). We gathered CT images and clinical data from 98 patients, who underwent intensity-modulated radiation therapy (IMRT) for head and neck cancers with a planned total dose of 70.0 Gy (33-35 fractions). During the 28-month (median) follow-up 27 patients (28%) developed RIHT. For each patient, we extracted 1316 radiomic features from original and transformed images using manually contoured thyroid masks. Creating models based on clinical, radiomic features or a combination thereof, we considered 3 variants of data preprocessing. Based on their performance metrics (sensitivity, specificity), we picked best models for each variant ((0.8, 0.96), (0.9, 0.93), (0.9, 0.89) variant-wise) and compared them with external NTCP models ((0.82, 0.88), (0.82, 0.88), (0.76, 0.91)). We showed that radiomic-based models did not outperform state-of-art NTCP models ( p > 0.05). The potential benefit of radiomic-based approach is that it is dose-independent, and models can be used prior to treatment planning allowing faster selection of susceptible population.
- Published
- 2021
- Full Text
- View/download PDF
22. Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models.
- Author
-
Nowicka Z, Tomasik B, Papis-Ubych A, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Wyka K, Fijuth J, Schoenfeld JD, Chałubińska-Fendler J, and Fendler W
- Abstract
We aimed to externally validate five normal tissue complication probability (NTCP) models for radiation-induced hypothyroidism (RIHT) in a prospectively recruited cohort of 108 patients with oropharyngeal cancer (OPC). NTCP scores were calculated using original published formulas. Plasma thyrotropin (TSH) level was additionally assessed in the short-term after RT. After a median of 28 months of follow-up, thirty one (28.7%) patients developed RIHT. Thyroid mean dose and thyroid volume were significant predictors of RIHT: odds ratio equal to 1.11 (95% CI 1.03-1.19) for mean thyroid dose and 0.87 (95%CI 0.81-0.93) for thyroid volume in univariate analyses. Two of the evaluated NTCP models, published by Rønjom et al. and by Boomsma et al., had satisfactory performance with accuracies of 0.87 (95%CI 0.79-0.93) and 0.84 (95%CI: 0.76-0.91), respectively. Three remaining models, by Cella et al., Bakhshandeh et al. and Vogelius et al., performed significantly worse, overestimating the risk of RIHT in this patient cohort. A short-term TSH level change relative to baseline was not indicative of RIHT development in the follow-up (OR 0.96, 95%CI: 0.65-1.42, p = 0.825). In conclusion, the models by Rønjom et al. and by Boomsma et al. demonstrated external validity and feasibility for long-term prediction of RIHT in survivors of OPC treated with Intensity-Modulated Radiation Therapy (IMRT).
- Published
- 2020
- Full Text
- View/download PDF
23. Can human myocardium be remotely preconditioned? The results of a randomized controlled trial.
- Author
-
Deja MA, Piekarska M, Malinowski M, Wiaderkiewicz R, Czekaj P, Machej L, Węglarzy A, Kowalówka A, Kołodziej T, Czech E, Plewka D, Mizia M, Latusek T, and Szurlej B
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers blood, Coronary Artery Disease surgery, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Reperfusion Injury blood, Treatment Outcome, Young Adult, Coronary Artery Bypass adverse effects, Ischemic Preconditioning, Myocardial methods, Myocardial Reperfusion Injury prevention & control, Postoperative Complications prevention & control, Troponin T blood
- Abstract
Objectives: No experimental study has shown that the myocardium of a remotely preconditioned patient is more resistant to a standardized ischaemic/hypoxic insult., Methods: This was a single-centre randomized (1:1), double-blinded, sham-controlled, parallel-group study. Patients referred for elective coronary bypass surgery were allocated to either remote ischaemic preconditioning (3 cycles of 5-min ischaemia/5-min reperfusion of the right arm using a blood pressure cuff inflated to 200 mmHg) or sham intervention. One hundred and thirty-four patients were recruited, of whom 10 dropped out, and 4 were excluded from the per-protocol analysis. The right atrial trabecula harvested on cannulation for cardiopulmonary bypass was subjected to 60 min of simulated ischaemia and 120 min of reoxygenation in an isolated organ experiment. Postoperative troponin T release and haemodynamics were assessed in an in vivo study., Results: The atrial trabeculae obtained from remotely preconditioned patients recovered 41.9% (36.3-48.3) of the initial contraction force, whereas those from non-preconditioned patients recovered 45.9% (39.1-53.7) (P = 0.399). Overall, the content of cleaved poly (ADP ribose) polymerase in the right atrial muscle increased from 9.4% (6.0-13.5) to 19.1% (13.2-23.8) (P < 0.001) after 1 h of ischaemia and 2 h of reperfusion in vitro. The amount of activated Caspase 3 and the number of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells also significantly increased. No difference was observed between the remotely preconditioned and sham-treated myocardium. In the in vivo trial, the area under the curve for postoperative concentration of troponin T over 72 h was 16.4 ng⋅h/ml (95% confidence interval 14.2-18.9) for the remote ischaemic preconditioning and 15.5 ng⋅h/ml (13.4-17.9) for the control group in the intention-to-treat analysis. This translated into an area under the curve ratio of 1.06 (0.86-1.30; P = 0.586)., Conclusions: Remote ischaemic preconditioning with 3 cycles of 5-min ischaemia/reperfusion of the upper limb before cardiac surgery does not make human myocardium more resistant to ischaemia/reperfusion injury., Clinical Trial Registration Number: NCT01994707., (© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
24. Remote Ischaemic PrEconditioning of Human Myocardium (RIPE): study protocol for a double-blinded randomised controlled trial.
- Author
-
Deja MA, Wiaderkiewicz R, Czekaj P, Czech E, Malinowski M, Machej L, Węglarzy A, Kowalówka A, Piekarska M, Szurlej B, and Latusek T
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Coronary Artery Bypass, Humans, Male, Middle Aged, Myocardial Reperfusion Injury enzymology, Myocardium enzymology, Research Design, Treatment Outcome, Troponin T blood, Young Adult, Ischemic Preconditioning, Myocardial, Myocardial Reperfusion Injury prevention & control
- Abstract
Background: Remote preconditioning has been shown to be a potent protective phenomenon in many animals. Several studies aimed to demonstrate it was feasible in humans by trying to show its protective effect during cardiac surgery. Of these, some small studies and one larger trial were positive while two other bigger studies showed no effectiveness of remote preconditioning as assessed by levels of postoperatively released cardiac markers. Recently, two large clinical trials also failed to prove the benefit of remote preconditioning in cardiac surgery. No study showed that remote preconditioning actually increases resistance of human myocardium to standardised ischaemic and reperfusion stimulus in experimental settings. In animal studies, remote preconditioning was shown to improve mitochondrial function and structure, but such data on human myocardium are scarce., Aim: The aim of the study is to determine whether remote preconditioning protects human myocardium against ischaemia-reperfusion injury in both in vivo and in vitro conditions., Methods: The trial is designed as a single-centre, double-blinded, sham-controlled trial of 120 patients. We randomise (1:1) patients referred for coronary artery bypass grafting for stable coronary artery disease to remote preconditioning or "sham" intervention. The remote preconditioning is obtained by three cycles of 5 min inflation and 5 min deflation of a blood pressure cuff on the right arm. Postoperative course including myocardial enzymes profile will be analysed. Moreover, in the in-vitro arm the clinically preconditioned myocardium will be assessed for function, mitochondria structure, and mitochondria-dependent apoptosis. The informed consent of all patients is obtained before enrolment into the study by the investigator. The study conforms to the spirit and the letter of the declaration of Helsinki., Results and Conclusions: In case the effect of remote preconditioning is not measurable in ex-vivo assessment, any future attempt at implementing this phenomenon in clinical practice may be futile and should not be continued until the effect can be confirmed in a controlled experimental setting. The study might therefore indicate future directions in trials of clinical implementation of remote preconditioning., Trial Registration: Clinical Trials Register (Clinicaltrials.gov) identifier: NCT01994707. The study was approved by Institutional Review Board of the Medical University of Silesia (KNW/0022/KB1/160/12).
- Published
- 2018
- Full Text
- View/download PDF
25. Postoperative serum troponin T concentration in patients undergoing aortic valve replacement does not predict early postoperative outcome.
- Author
-
Piekarska ML, Szurlej B, Latusek T, Wdowik G, and Deja MA
- Subjects
- Aged, Area Under Curve, Biomarkers blood, Female, Humans, Logistic Models, Male, Postoperative Complications etiology, Predictive Value of Tests, Treatment Outcome, Aortic Valve Insufficiency surgery, Aortic Valve Stenosis surgery, Heart Valve Prosthesis Implantation adverse effects, Postoperative Complications blood, Troponin T blood
- Abstract
Background: The measurement of serum cardiac troponin T concentration (cTnT) after aortic valve replacement (AVR) provides the opportunity to assess the degree of myocardial damage and may have some prognostic value., Aim: To determine whether elevated troponin level is related to patient outcome., Methods: We investigated patient outcome and postoperative serum concentration of troponin T in 79 patients who underwent AVR. Serum levels of cTnT were measured within 24 h of AVR. We searched for the occurrence of subsequent adverse events i.e. requirement for intraaortic ballon pump (IABP) or inotropic support, prolonged Intensive Care Unit (ICU) stay, and in-hospital death., Results: Serum concentration of cTnT after AVR increased significantly compared to the preoperative value. We found significant positive correlations between aortic cross-clamp time (r = 0.23, p = 0.04), cardiopulmonary bypass time (r = 0.4,p = 0.00029), duration of the surgery (r = 0.30, p = 0.008), and postoperative cTnT level. Three (4%) patients required IABP support, 37 (46%) patients required inotropic support, and 11 (14%) patients had a prolonged ICU stay (> 48 h). Thirty eight (48%) patients required either inotropic support or IABP insertion. At least one adverse event occurred in 44 (56%) patients. Median postoperative serum cTnT concentration was 0.31 ng/mL (interquartile range 0.23-0.60 ng/mL). We failed to find a statistically significant difference in postoperative cTnT level between patients with and without adverse events. According to multiple logistic regression analysis, the postoperative serum level of troponin T was not independently associated with adverse patient outcome. Diabetes mellitus, patient age and left ventricular ejection fraction below 50% were significant independent predictors of adverse events after AVR. The area under receiver operating curve (AUROC) for postoperative serum troponin T concentration as a determinant of various adverse outcomes was never significantly different from 0.50., Conclusions: Serum cTnT concentration is frequently - if not universally - elevated after AVR. Serum level of troponin T measured on the first postoperative morning is a poor predictor of patient outcome after AVR and should not be relied on when planning postoperative care.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.